In 2014 synlab services GmbH purchased INTERLAB GmbH central lab services – worldwide (INTERLAB). In September, INTERLAB merged with synlab Umweltinstitut GmbH, and consequently all documentation carries the synlab logo and will refer to the synlab pharma institute, Munich location, a division of synlab Umweltinstitut GmbH.
Please note that Dr. Hermann Schulz, Chief Executive Officer of INTERLAB until August 31st, 2015, will continue as a Legal Representative (“Prokurist”) of synlab Umweltinstitut GmbH. He will also head the synlab pharma institute as its Executive Vice President.
INTERLAB and synlab have been successfully cooperating since 2004. Hence, no impact on the day to day business or on the handling of study samples is to be expected. Our address, shipping logistics, and contractual terms shall not undergo any modifications. Although email addresses will switch form name@interlab.de to name@synlab.com your messages will automatically be re-routed.
As the new contractual partner, synlab Umweltinstitut GmbH shall overtake all duties and responsibilities of INTERLAB. Although invoices will be issued by synlab Umweltinstitut GmbH (using their tax ID: DE 195 993 312) the bank account at Deutsche Bank AG MuÌnchen will remain unchanged by the moment.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Oveporexton Shows Superior Efficacy in Phase II Narcolepsy Type 1 Trial Without Hepatotoxicity
May 16th 2025In the TAK-861-2001 Phase IIb study, oveporexton significantly improved wakefulness, daytime sleepiness, and cataplexy frequency in patients with narcolepsy type 1, outperforming current therapies and avoiding liver toxicity seen with earlier OX2R agonists, according to results published in The New England Journal of Medicine.